Pharmacoresistance: Modern concept and basic data derived from human brain tissue

Epilepsia

Volumn 44, Issue SUPPL. 5, 2003, Pages 9-15

  Elger, Christian E ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANTICONVULSANT THERAPY; BRAIN TISSUE; CONFERENCE PAPER; DISEASE CONTROL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HUMAN; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SUDDEN DEATH; SUICIDAL BEHAVIOR; TREATMENT FAILURE;

EID: 0043072971     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.44.s.5.3.x     Document Type: Conference Paper

References (33)

1. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(suppl 5):S2-8.
2. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
3. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001;42:357-62.
4. Sillanpaa M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Eng J Med 1998;338:1715-22.
5. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002;58(suppl 5):S21-6.
6. Pitkanen A. Drug-mediated neuroprotection and antiepileptogenesis: animal data. Neurology 2002;59(suppl 5):S27-33.
7. Krupp E, Heynen T, Li XL, et al. Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: crosstolerance to carbamazepine but not valproate or diazepam. Exp Neurol 2000;162:278-89.
8. Weiss SR, Post RM. Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. Clin Neuropharmacol 1987;10:272-9.
9. Nashef L, Fish DR, Sander JW, Shorvon SD. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 1995;58:462-4.
10. Kanner AM, Nieto JC. Depressive disorders in epilepsy. Neurology 1999;53(suppl 2):S26-32.
11. Buck D, Baker GA, Jacoby A, Smith DF, Chadwick DW. Patients' experiences of injury as aresult of epilepsy. Epilepsia 1997;38:439-44.
12. Hennessy MJ, Elwes RD, Rabe-Hesketh S, Binnie CD, Polkey CE. Prognostic factors in the surgical treatment of medically intractable epilepsy associated with mesial temporal sclerosis. Acta Neurol Scand 2001;103:344-50.
13. Holmes MD, Dodrill CB, Ojemann GA, Wilensky AJ, Ojemann LM. Outcome following surgery in patients with bitemporal interictal epileptiform patterns. Neurology 1997;48:1037-40.
14. Wieser HG, Siegel AM. Analysis of foramen ovale electrode-recorded seizures and correlation with outcome following amygdalohippocampectomy. Epilepsia 1991;32:838-50.
15. Salanova V, Andermann F, Rasmussen T, Olivier A, Quesney L. The running down phenomenon in temporal lobe epilepsy. Brain 1996;119:989-96.
16. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002;58(suppl 5):S9-20.
17. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Eng J Med 2001;345:311-8.
18. Buchfelder M, Fahlbusch R, Ganslandt O, Stefan H, Nimsky C. Use of intraoperative magnetic resonance imaging in tailored temporal lobe surgeries for epilepsy. Epilepsia 2002;43:864-73.
19. Dichter MA, Cole AJ. Neuroprotection and antiepileptogenesis: where are we now? Neurology 2002;59(suppl 5):S36-8.
20. Blumcke I, Thom M, Wiestler OD. Ammon's Horn Sclerosis: a maldevelopmental disorder associated with temporal lobe epilepsy. Brain Pathology 2002;12:199-211.
21. Pitkanen A, Sutula T. Is epilepsy a progressive disease? Prospects for new therapeutic approaches in temporal lobe epilepsy. Lancet Neurol 2002;1:173-81.
22. Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol 2002;15:179-84.
23. Liang LP, Ho YS, Patel M. Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 2000;101:563-70.
24. Sisodiya SM, Lin W-R, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: human epilepsy. Novartis Found Symp 2002;243:167-74.
25. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
26. Sisodiya SM, Lin W-R, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
27. Frey HH, Loscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 1978;17:637-42.
28. Shen DD. Valproate: absorption, distribution, and excretion. In: Loscher W, ed. Valproate. Birkhauser: Basel. 1999:77-90.
29. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
30. Kohling R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002;43:1278-95.
31. +-channel betal subunit gene SCN1B. Nat Genet 1998;19:366-70.
32. Lombardo AJ, Kuzniecky R, Powers RE, Brown GB. Altered brain sodium channel transcript levels in human epilepsy. Mol Brain Res 1996;35:84-90.
33. Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003;53:469-79.